<DOC>
	<DOC>NCT00885820</DOC>
	<brief_summary>This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection versus a non-protocol biopsy control group.</brief_summary>
	<brief_title>Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subject is the recipient of a first or second cadaveric or living donor mismatched (at least one mismatch) renal transplant If female and of childbearing potential, subject has a negative pregnancy test and utilizes adequate contraceptive methods Recipients of a kidney from a donor over 65 years of age Recipient of nonrelated donor kidney with peak pretransplant PRA &gt; 50 Subject has lost a previous graft to rejection less than one year from transplant Subject who has received an investigational drug within three months prior to randomization Subjects who are pregnant or breastfeeding Subject receives a kidney lacking a preimplantation biopsy Subject has significant disease or disability (e.g. malignancy or uncontrolled infection) which prevents adherence to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Graft Survival</keyword>
</DOC>